University of Pennsylvania
Wynnewood, PA, United States
Dr. Victoria Werth is a Professor of Dermatology and Medicine at the University of Pennsylvania School of Medicine and Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital. Dr. Werth earned her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She completed a residency in internal medicine at Northwestern Memorial Hospital in Chicago, Illinois, and dermatology residency and immunodermatology fellowship at New York University School of Medicine in New York. She joined the faculty at Penn in 1989 and has developed an internationally recognized program in autoimmune skin diseases.
Interferons and Rheumatic Skin Disease
Sunday, November 17, 2024
10:00 AM – 10:20 AM Eastern Time
Disclosure(s): Abbvie: Consultant (Ongoing); Alpine Immune Sciences: Consultant (Ongoing); Amgen: Consultant (Terminated, January 15, 2024), Grant/Research Support (Terminated, January 15, 2024); Anaptysbio: Consultant (Ongoing); Argenx: Consultant (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Cabaletta: Consultant (Ongoing); Calyx: Consultant (Ongoing); Caribou: Consultant (Ongoing); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cugene: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); EMD Serona: Consultant (Ongoing); Evommune: Consultant (Ongoing); Gilead: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Horizon: Consultant (Ongoing), Grant/Research Support (Ongoing); Immunovant: Consultant (Ongoing); Innovaderm: Consultant (Ongoing); Janssen: Consultant (Ongoing); Kwoya Kirin: Consultant (Ongoing); Merck: Consultant (Ongoing); Nektar: Consultant (Ongoing); Nuvig: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Priovant: Consultant (Ongoing), Grant/Research Support (Ongoing); Regeneron: Consultant (Ongoing), Grant/Research Support (Ongoing); Rome Pharmaceuiticals: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); Takdea: Consultant (Ongoing); UCB: Consultant (Ongoing); Ventus: Consultant (Ongoing), Grant/Research Support (Ongoing); Xencor: Consultant (Ongoing)
Sunday, November 17, 2024
11:00 AM – 11:30 AM Eastern Time
Disclosure(s): Abbvie: Consultant (Ongoing); Alpine Immune Sciences: Consultant (Ongoing); Amgen: Consultant (Terminated, January 15, 2024), Grant/Research Support (Terminated, January 15, 2024); Anaptysbio: Consultant (Ongoing); Argenx: Consultant (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Cabaletta: Consultant (Ongoing); Calyx: Consultant (Ongoing); Caribou: Consultant (Ongoing); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cugene: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); EMD Serona: Consultant (Ongoing); Evommune: Consultant (Ongoing); Gilead: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Horizon: Consultant (Ongoing), Grant/Research Support (Ongoing); Immunovant: Consultant (Ongoing); Innovaderm: Consultant (Ongoing); Janssen: Consultant (Ongoing); Kwoya Kirin: Consultant (Ongoing); Merck: Consultant (Ongoing); Nektar: Consultant (Ongoing); Nuvig: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Priovant: Consultant (Ongoing), Grant/Research Support (Ongoing); Regeneron: Consultant (Ongoing), Grant/Research Support (Ongoing); Rome Pharmaceuiticals: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); Takdea: Consultant (Ongoing); UCB: Consultant (Ongoing); Ventus: Consultant (Ongoing), Grant/Research Support (Ongoing); Xencor: Consultant (Ongoing)